Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Barrett JR., Belij-Rammerstorfer S., Dold C., Ewer KJ., Folegatti PM., Gilbride C., Halkerston R., Hill J., Jenkin D., Stockdale L., Verheul MK., Aley PK., Angus B., Bellamy D., Berrie E., Bibi S., Bittaye M., Carroll MW., Cavell B., Clutterbuck EA., Edwards N., Flaxman A., Fuskova M., Gorringe A., Hallis B., Kerridge S., Lawrie AM., Linder A., Liu X., Madhavan M., Makinson R., Mellors J., Minassian A., Moore M., Mujadidi Y., Plested E., Poulton I., Ramasamy MN., Robinson H., Rollier CS., Song R., Snape MD., Tarrant R., Taylor S., Thomas KM., Voysey M., Watson MEE., Wright D., Douglas AD., Green CM., Hill AVS., Lambe T., Gilbert S., Pollard AJ.

DOI

10.1038/s41591-020-01179-4

Type

Journal article

Journal

Nature Medicine

Publisher

Springer Science and Business Media LLC

Publication Date

02/2021

Volume

27

Pages

279 - 288

Permalink Original publication